<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209352</url>
  </required_header>
  <id_info>
    <org_study_id>FHCRC IR 420</org_study_id>
    <secondary_id>CA 18029</secondary_id>
    <secondary_id>CA 15704</secondary_id>
    <secondary_id>Burroughs Wellcome Fund</secondary_id>
    <secondary_id>FHCRC Protocol 236.00</secondary_id>
    <nct_id>NCT00209352</nct_id>
  </id_info>
  <brief_title>Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant</brief_title>
  <official_title>Randomized Trial of Long-Term Oral Acyclovir Usage to Prevent Varicella Zoster Virus Infection After Allogeneic Bone Marrow Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Burroughs Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      The objective of this study is to prevent reactivation of herpes zoster during the first year
      after transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Herpes zoster infection occurs in 30% of allogeneic hematopoietic cell transplant (HCT)
      recipients who had a history of varicella zoster virus (VZV) infection. A safe and effective
      prevention strategy has not been established.

      77 marrow allograft recipients at risk for VZV reactivation were randomized to oral acyclovir
      800 mg twice daily or placebo given from day 30 until day 365 and were followed for toxicity
      and clinical evidence of herpes zoster infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1985</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VZV infection at one year</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>VZV infection after discontinuation of prophylaxis</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>VZV Infection After Bone Marrow Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  10 years or older

          -  Both sex (male or female)

          -  Allogeneic transplant patient for hematologic malignancy or aplastic anemia

        Exclusion Criteria:

          -  Previous intolerance to acyclovir

          -  Patients who are unavailable for follow-up

          -  Patients in whom drug compliance may be a problem

          -  Evidence of active VZV infection

          -  VZV infection in the initial 1 month after transplant

          -  Pregnant women, lactating women, or those not using adequate contraception

          -  Creatinine &gt; 3.0 mg/dl.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Boeckh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study. Blood. 2006 Mar 1;107(5):1800-5. Epub 2005 Nov 10.</citation>
    <PMID>16282339</PMID>
  </results_reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>December 17, 2007</last_update_submitted>
  <last_update_submitted_qc>December 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2007</last_update_posted>
  <keyword>Varicella Zoster Virus Infection</keyword>
  <keyword>VZV infection</keyword>
  <keyword>Oral Acyclovir</keyword>
  <keyword>Allogeneic Bone Marrow Transplantation</keyword>
  <keyword>Allogeneic Hematopoietic Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

